"On 3 February 2020, PYC advised that work had begun on 6 new discovery programs targeting retinal diseases." Unsure if this was inclusive or exclusive of the RP lead candidate, but lets be cautious and include it.)
We now know 3 of the targeted conditions: 1.Retina Pigmentosa. 2.Diabetic Retinopathy and age-related Macular Degeneration. ( Both released to ASX together on 5th October. ) 3.Autosomal Dominant Optic Atrophy (ADOA) caused by mutations in the OPA1 gene. (released to ASX on 12th October and stated to be the 3rd drug development programme. (i.e. Diabetic Retinopathy and Macular Degeneration is classed as 1 programme not 2 separate ones.)
So we still have at least 3 MORE targeted eye conditions to be released either this, or next quarter. From the Oct Investor Presentation we also have a CNS (Central Nervous System) candidate due early next year. We have Rabbit Toxicology tests due next quarter. And soon to be released is news of Orphan Drug Designation for VP-001. Above is only looking forward to 1st quarter of next year!
A lot of very imminent upside potential IMHO! Long term hold for me!!
PYC Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)